ALLMedicine™ Essential Thrombocythemia Center
Research & Reviews 851 results
https://clinicaltrials.gov/ct2/show/NCT03755518
May 16th, 2022 - This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV M...
https://doi.org/10.1007/s40265-022-01718-y 10.1007/s11899-020-00596-z 10.2217/fon.15.200 10.2147/JEP.S110702 10.1038/leu.2011.148 10.2147/JEP.S150729 10.1186/s13045-016-0367-x 10.2174/1872312809666150119105250 10.1001/jamaoncol.2017.5818 10.1016/S2352-3026(17)30027-3 10.3324/haematol.2021.279415 10.1182/bloodadvances.2020003314 10.1182/blood-2013-02-484832 10.1158/1078-0432.CCR-20-4725
Drugs Lamb YN
May 15th, 2022 - Pacritinib (VONJO™) is an orally administered, small molecule kinase inhibitor being developed by CTI BioPharma for the treatment of myelofibrosis and graft-versus-host disease. Pacritinib received its first approval in February 2022 in the USA fo...
https://clinicaltrials.gov/ct2/show/NCT02953704
May 13th, 2022 - The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofib...
https://doi.org/10.1055/a-1849-8477
Thrombosis and Haemostasis; Nicol C, Ajzenberg N et. al.
May 12th, 2022 - The management of myeloproliferative neoplasms (MPN) is based on the reduction of thrombosis risk. The incidence, impact, and risk factors of bleedings have been less studied. All patients with polycythemia vera (n=339) or essential thrombocythemi...
https://clinicaltrials.gov/ct2/show/NCT01387763
Apr 27th, 2022 - Chronic myeloid neoplasms (CMPN) consists of three main entities, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders have many overlapping clinical features. The diseases are clonal stem c...
Guidelines 3 results
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.
Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.
Dec 14th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...
https://doi.org/10.1007/s00277-014-2224-8
Annals of Hematology; Kreher S, Ochsenreither S et. al.
Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...
Drugs 3 results see all →
Clinicaltrials.gov 37 results
https://clinicaltrials.gov/ct2/show/NCT03755518
May 16th, 2022 - This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV M...
https://clinicaltrials.gov/ct2/show/NCT02953704
May 13th, 2022 - The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofib...
https://clinicaltrials.gov/ct2/show/NCT01387763
Apr 27th, 2022 - Chronic myeloid neoplasms (CMPN) consists of three main entities, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders have many overlapping clinical features. The diseases are clonal stem c...
https://clinicaltrials.gov/ct2/show/NCT04262141
Apr 14th, 2022 - The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.
https://clinicaltrials.gov/ct2/show/NCT02934477
Mar 21st, 2022 - Patients with primary MF (PMF), post-essential thrombocythemia (ET) MF, or post-polycythemia vera (PV) MF, with intermediate-2 or high-risk disease as determined by the DIPSS, and aged ≥55 at the time of DIPSS assessment are eligible for this stud...
News 79 results
https://www.onclive.com/view/pacritinib-paves-a-unique-lane-of-treatment-for-select-myelofibrosis
Apr 5th, 2022 - Patients who develop post–essential thrombocythemia myelofibrosis (PET-MF) or post–polycythemia vera myelofibrosis (PPV-MF), which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effecti...
https://www.onclive.com/view/unmet-needs-and-potential-advances-in-mpn-and-mf
Mar 7th, 2022 - Ruben Mesa, MD: Let’s pivot in terms of new therapies and some of the unmet needs. We’re mindful from this year [2021] at the American Society of Hematology [ASH annual meeting], a range of additional mechanisms of action that are being looked at....
https://www.medscape.com/viewarticle/969389
Mar 1st, 2022 - The US Food and Drug Administration (FDA) has granted accelerated approval for a new drug for the treatment of myelofibrosis, the first specifically for patients with low platelet counts. Pacritinib (Vonjo, CTI BioPharma) is indicated for use in t...
https://www.onclive.com/view/an-introduction-to-myeloproliferative-neoplasms
Feb 17th, 2022 - Ruben Mesa, MD:Hello and welcome to this OncLive® Peer Exchange titled Myeloproliferative Neoplasms. I’m Dr Ruben Mesa, the executive director of the Mays Cancer Center at UT Health San Antonio MD Anderson. Joining me in today’s discussions are my...
https://www.onclive.com/view/understanding-essential-thrombocythemia-and-treatment-options
Jan 25th, 2022 - Ruben Mesa, MD: So Stephen, why don’t we start with some of that earlier phase of disease? Why don’t you walk us through ET [essential thrombocythemia]? What are some of the key things we need to be aware of in terms of ET? Stephen Oh, MD, PhD:...
